Generic Name:
esketamine hydrochloride
Project Status:
Complete
Therapeutic Area:
Major depressive disorder (MDD), adults
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Spravato
Project Line:
Reimbursement Review
Project Number:
SR0621-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Indicated in combination with a SSRI or SNRI, for the treatment of major depressive disorder in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated in combination with a SSRI or SNRI, for the treatment of major depressive disorder in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.